Clinical Utility of Intravenous Nifekalant Injection during Radiofrequency catheter Ablation for Persistent Atrial Fibrillation

摘要

Background Radiofrequency catheter ablation (RFCA) for persistent atrial fibrillation (AF) is still challenging even in RFCA-era for AF. The aim of this study was to assess the clinical utility of nifekalant, a pure potassium channel blocker, during RFCA for persistent AF. Methods and results We retrospectively enrolled 157 consecutive persistent AF patients undergoing first RFCA procedure with complex fractionated atrial electrogram (CFAE) ablation after pulmonary veins isolation and compared outcomes between patients with (NFK group: N=79) and without (No-NFK group: N=78) additional CFAE ablation using intravenous nifekalant (0.3mg/kg). Primary endpoint was 24-month atrial arrhythmia-free survival post ablation. The prevalence of AF termination was significantly higher in NFK group than No-NFK group (64.6% versus 7.7%, P.